Etienne Humblin

Etienne Humblin

Auto-generated profile, based on publicly available information

Etienne Humblin

Marc and Jennifer Lipschultz Precision Immunology Institute, ISMMS, NY, NY, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 June 2015 in Nature Immunology
Verified
Journal Article
Closed access
Mélanie BruchardMélanie Bruchard
Mélanie Bruchard
CRCédric REBE
Cédric REBE
VDValentin Derangère
Valentin Derangère
DTDieudonnée Togbé
Dieudonnée Togbé
BRBernhard Ryffel
Bernhard Ryffel
Ghiringhelli FrançoisGhiringhelli François
Ghiringhelli François

22 January 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
ACAlexia Karen Cotte
Alexia Karen Cotte
VAVirginie Aires
Virginie Aires
MFMaxime Fredon
Maxime Fredon
ELEmeric Limagne
Emeric Limagne
VDValentin Derangère
Valentin Derangère
Dominique DelmasDominique Delmas
Dominique Delmas
Lipid droplet (LD) accumulation is a now well-recognised hallmark of cancer. However, the significance of LD accumulation in colorectal cancer (CRC) biology is incompletely understood under chemotherapeutic conditions. Since drug resistance is a major obstacle to treatment success, we sought to determine the contribution of LD accumulation to chemotherapy resistance in CRC. Here we show that LD content of CRC cells positively correlates with the expression of lysophosphatidylcholine acyltransferase 2 (LPCAT2), an LD-localised enzyme supporting phosphatidylcholine synthesis. We also demonstrate that LD accumulation drives cell-death resistance to 5-fluorouracil and oxaliplatin treatments both in vitro and in vivo. Mechanistically, LD accumulation impairs caspase cascade activation and ER stress responses. Notably, droplet accumulation is associated with a reduction in immunogenic cell death and CD8+ T cell infiltration in mouse tumour grafts and metastatic tumours of CRC patients. Collectively our findings highlight LPCAT2-mediated LD accumulation as a druggable mechanism to restore CRC cell sensitivity.

1 April 2017 in Cell Reports
Verified
Journal Article
Open access
ELEmeric Limagne
Emeric Limagne
MTMarion Thibaudin
Marion Thibaudin
RERomain Euvrard
Romain Euvrard
HBHélène Berger
Hélène Berger
PCPauline Chalons
Pauline Chalons
Ghiringhelli FrançoisGhiringhelli François
Ghiringhelli François
Sirtuin-1 deacetylates proteins and has emerged as a critical regulator of different cellular processes, particularly inflammation. Basal SIRT1 activity was previously found to limit Th9 and enhance Th17 differentiation in mice, but the effect of pharmacological SIRT1 activation on T cell differentiation and antitumor responses remains unclear. Here, we find that SIRT1 pharmacological agonists selectively impede mouse and human Th17 cell differentiation. SIRT1 activation induces STAT3 deacetylation, thus reducing its ability to translocate into the nucleus, bind to Rorc promoter, and induce its transcription. SIRT1 agonists reduce tumor growth in mice by blocking Th17 cell differentiation. In cancer patients, the SIRT1 agonist metformin reduced the frequency of Th17 cells and STAT3 acetylation levels. Altogether, these data underscore that SIRT1 activation impedes Th17 cell differentiation and thereby limits tumor growth and suggest that SIRT1 activators may directly target IL-17A functions.

4 August 2023 in Science Immunology
Verified
Journal Article
Closed access
EHEtienne Humblin
Etienne Humblin
IKIsabel Korpas
Isabel Korpas
JLJiahua Lu
Jiahua Lu
DFDan Filipescu
Dan Filipescu
VHVerena van der Heide
Verena van der Heide
AKAlice O. Kamphorst
Alice O. Kamphorst
During persistent antigen stimulation, such as in chronic infections and cancer, CD8 T cells differentiate into a hypofunctional programmed death protein 1–positive (PD-1 + ) exhausted state. Exhausted CD8 T cell responses are maintained by precursors (Tpex) that express the transcription factor T cell factor 1 (TCF-1) and high levels of the costimulatory molecule CD28. Here, we demonstrate that sustained CD28 costimulation is required for maintenance of antiviral T cells during chronic infection. Low-level CD28 engagement preserved mitochondrial fitness and self-renewal of Tpex, whereas stronger CD28 signaling enhanced glycolysis and promoted Tpex differentiation into TCF-1 neg exhausted CD8 T cells (Tex). Furthermore, enhanced differentiation by CD28 engagement did not reduce the Tpex pool. Together, these findings demonstrate that continuous CD28 engagement is needed to sustain PD-1 + CD8 T cells and suggest that increasing CD28 signaling promotes Tpex differentiation into more functional effector-like Tex, possibly without compromising long-term responses.

10 November 2016 in Seminars in Immunopathology
Verified
Journal Article
Open access
PDF file
TVThaiz Rivera Vargas
Thaiz Rivera Vargas
EHEtienne Humblin
Etienne Humblin
Frederique VEGRANFrederique VEGRAN
Frederique VEGRAN
Ghiringhelli FrançoisGhiringhelli François
Ghiringhelli François
LALionel Apetoh
Lionel Apetoh
IL-9 was initially identified as a T cell growth factor with a potential oncogenic activity. Accordingly, IL-9 drives tumor growth in most hematological cancers. However, the links between IL-9 and cancer progression have been recently revisited following the discovery of TH9 cells. TH9 cells, which have been characterized in 2008 as a proinflammatory CD4 T cell subset that promotes protection against parasites and drives tissue inflammation in colitis, actually harbor potent IL-9-dependent anti-cancer properties in solid tumors and especially melanoma. While the molecular mechanisms underlying these observations are still being investigated, TH9 cells were demonstrated to activate both innate and adaptive immune responses, thereby favoring anti-cancer immunity and tumor elimination. Human TH9 cells have also been identified in cancer tissues, but their functions remain elusive. The present review aims to discuss the anti-cancer potential of TH9 cells and their possible clinical relevance for cancer immunotherapy.

27 December 2016 in Oncotarget
Verified
Journal Article
Open access
FDFlorent Dufour
Florent Dufour
TRThibault Rattier
Thibault Rattier
ACAndrei Alexandru Constantinescu
Andrei Alexandru Constantinescu
LZLuciana Zischler
Luciana Zischler
AMAymeric Morlé
Aymeric Morlé
OMOlivier Micheau
Olivier Micheau
TRAIL receptor gene editing unveils TRAIL-R1 as a master player of apoptosis induced by TRAIL and ER stres